アリヴェクシス㈱
Tokyo, JP · 5 known investors
Find your way into アリヴェクシス㈱
1 people in our graph share verified history with the アリヴェクシス㈱ team — schools, employers, funds. One of them is your warm intro.
Alivexis is a drug discovery company that develops small molecule therapeutics targeting cancer, immune-inflammatory conditions, and rare diseases, leveraging computational platforms and disease biology expertise across operations in Japan and the US.
Founders & leadership
SR
S. Roy KimurainCofounder & CEOS. Roy Kimura has more than 20 years of experience in drug discovery R&D, business development, and consulting, including roles at Fortune 500 pharmaceutical companies and startup ventures, with expertise in pre-clinical drug discovery, computational modeling, and machine learning. He is cofounder and CEO of Alivexis, a drug discovery company developing small molecule therapeutics for cancer, immune-inflammatory conditions, and rare diseases.
KO
Kazuki OhnoCofounder & COO
Investors · 5
Competitors · 4
by search overlap
Exelixis14 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Bioworld11 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Scynexis10 shared keywordsSCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections. The company focuses on rare diseases affecting underserved patient populations.
Alumis9 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Companies competing with アリヴェクシス㈱ for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does アリヴェクシス㈱ do?
- Alivexis is a drug discovery company that develops small molecule therapeutics targeting cancer, immune-inflammatory conditions, and rare diseases, leveraging computational platforms and disease biology expertise across operations in Japan and the US.
- Who founded アリヴェクシス㈱?
- アリヴェクシス㈱ was founded by S. Roy Kimura, Kazuki Ohno.
- Who are アリヴェクシス㈱'s investors?
- アリヴェクシス㈱'s investors include SMBC Venture Capital, DBJ Capital, Fast Track Initiative, Mobile Internet Capital, Inc., UTokyo Innovation Platform Co. Ltd..
- Where is アリヴェクシス㈱ headquartered?
- アリヴェクシス㈱ is headquartered in Tokyo, JP.